Safety, tolerability and risk benefit analysis of tiotropium in COPD

References

• AnthonisenNRConnettJEEnrightPL2002Hospitalizations and mortality in the Lung Health StudyAm J Respir Crit Care Med166333912153966
   PubMed Web of Science ®Google Scholar
• AnthonisenNRSkeansMAWiseRA2005The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trialAnn Intern Med142233915710956
   PubMed Web of Science ®Google Scholar
• BarnesPJ2000The pharmacological properties of tiotropiumChest11763S6610673478
   PubMed Web of Science ®Google Scholar
• BarrRGManagement of chronic obstructive pulmonary disease2004JAMA29110667 author reply 106714996770
   PubMed Web of Science ®Google Scholar
• BarrRGBourbeauJCamargoCA2006Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysisThorax618546216844726
   PubMed Web of Science ®Google Scholar
• BatemanEDvan DykMSagriotisA2008Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot studyPulm Pharmacol Ther2120517118684
   PubMed Web of Science ®Google Scholar
• BenderBGPedanAVarastehLT2006Adherence and persistence with fluticasone propionate/salmeterol combination therapyJ Allergy Clin Immunol11889990417030244
   PubMed Web of Science ®Google Scholar
• Breekveldt-PostmaNSGerritsCMLammersJW2004Persistence with inhaled corticosteroid therapy in daily practiceRespir Med98752915303640
   PubMed Web of Science ®Google Scholar
• Breekveldt-PostmaNSKoerselmanJErkensJA2007Enhanced persistence with tiotropium compared with other respiratory drugs in COPDRespir Med101139840517368011
   PubMed Web of Science ®Google Scholar
• BriggsDDJrCovelliHLapidusR2005Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPDPulm Pharmacol Ther1839740416179215
   PubMed Web of Science ®Google Scholar
• BrusascoVHodderRMiravitllesM2003Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDThorax5839940412728159
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliB2007Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med3567758917314337
   PubMed Web of Science ®Google Scholar
• CasaburiRBriggsDDJrDonohueJF2000The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multi-center trial. The US Tiotropium Study GroupChest118129430211083677
   PubMed Web of Science ®Google Scholar
• CasaburiRKukafkaDCooperCB2005Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPDChest1278091715764761
   PubMed Web of Science ®Google Scholar
• CasaburiRMahlerDAJonesPW2002A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J192172411866001
   PubMed Web of Science ®Google Scholar
• CelliBRMacNeeW2004Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J239324615219010
   PubMed Web of Science ®Google Scholar
• ChanCKMaltaisFSigouinC2007A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary diseaseCan Respir J144657218060091
   PubMed Web of Science ®Google Scholar
• ChapmanKR1990The role of anticholinergic bronchodilators in adult asthma and chronic obstructive pulmonary diseaseLung1682953032143551
   PubMed Web of Science ®Google Scholar
• COMBIVENT Inhalation Aerosol Study Group1994In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trialChest105141198181328
   PubMed Web of Science ®Google Scholar
• CovelliHBhattacharyaSCassinoC2005Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary diseasePharmacotherapy2517081816305289
   PubMed Web of Science ®Google Scholar
• CramerJABradley-KennedyCScaleraA2007Treatment persistence and compliance with medications for chronic obstructive pulmonary diseaseCan Respir J1425917315055
   PubMed Web of Science ®Google Scholar
• CrinerGJSharafkhanehAPlayerR2008Efficacy of tiotropium inhalation powder in african-american patients with chronic obstructive pulmonary diseaseCOPD5354118259973
   PubMedGoogle Scholar
• DahlRGreefhorstLANowakD2001Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med1647788411549532
   PubMed Web of Science ®Google Scholar
• DisseBReichlRSpeckG1993Ba 679 BR, a novel long-acting anticholinergic bronchodilatorLife Sci52537448441333
   PubMed Web of Science ®Google Scholar
• DonohueJFMenjogeSKestenS2003Tolerance to bronchodilating effects of salmeterol in COPDRespir Med9710142014509555
   PubMed Web of Science ®Google Scholar
• DonohueJFvan NoordJABatemanED2002A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterolChest122475512114338
   PubMed Web of Science ®Google Scholar
• DusserDBravoMLIaconoP2006The effect of tiotropium on exacerbations and airflow in patients with COPDEur Respir J275475516507855
   PubMed Web of Science ®Google Scholar
• ErnstPGonzalezAVBrassardP2007Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumoniaAm J Respir Crit Care Med176162617400730
   PubMed Web of Science ®Google Scholar
• FishmanAMartinezFNaunheimK2003A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysemaN Engl J Med34820597312759479
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration2002Pulmonary-Allergy Drugs Advisory Committee. 2002 Clinical briefing documentIntegrated review of safety, NDA21395
   Google Scholar
• Food and Drug Administration2005FDA Public Health Advisory. Serevent Diskus (salmeterol xinafoate inhalation powder), Advair Diskus (fluticasone propionate and salmeterol inhalation powder), Foradil Aerolizer (formoterol fumarate inhalation powder)Accessed October, 2008 URL: http://www.fda.gov/cder/drug/advisory/LABA.htm
   Google Scholar
• Food and Drug Administration2008Early Communication about an Ongoing Safety Review of TiotropiumAccessed October, 2008 URL: http://www.fda.gov/cder/drug/early_comm/tiotropium.htm
   Google Scholar
• GlaxoSmithKline2005Clinical trial register for a multicenter, randomized, double-blind, double-dummy, parallel group, 8-week comparison of salmeterol xinafoate versus ipratropium bromide versus salmeterol xinafoate plus ipratropium bromide versus placebo in subjects with chronic obstructive pulmonary diseaseAccessed October, 2008 URL: http://www.gsk-clinicalstudyregister.com/files/pdf/2981.pdf
   Google Scholar
• GlaxoSmithKline2005Clinical trial register for a multicenter, randomized, double-blind, double-dummy, parallel-group, 8-week comparison of salmeterol xinafoate versus ipratropium bromide versus salmeterol xinafoate plus ipratropium bromide versus placebo in subjects with chronic obstructive pulmonary diseaseAccessed October, 2008 URL: http://www.gsk-clinicalstudyregister.com/files/pdf/2843.pdf
   Google Scholar
• GrossNJSkorodinMS1984Role of the parasympathetic system in airway obstruction due to emphysemaN Engl J Med31142156749189
   PubMed Web of Science ®Google Scholar
• KestenSJaraMWentworthC2006Pooled clinical trial analysis of tiotropium safetyChest130169570317166984
   PubMed Web of Science ®Google Scholar
• KrigsmanKNilssonJLRingL2007Refill adherence for patients with asthma and COPD: comparison of a pharmacy record database with manually collected repeat prescriptionsPharmacoepidemiol Drug Saf16441817006959
   PubMed Web of Science ®Google Scholar
• LeeTAPickardASAuDH2008Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary diseaseAnn Intern Med14963809018794557
   PubMed Web of Science ®Google Scholar
• MahlerDADonohueJFBarbeeRA1999Efficacy of salmeterol xinafoate in the treatment of COPDChest1159576510208192
   PubMed Web of Science ®Google Scholar
• Medical Research Council Working Party1981Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysemaLancet168166110912
   PubMed Web of Science ®Google Scholar
• MoitaJBarbaraCCardosoJ2008Tiotropium improves FEV1 patients with COPD irrespective of smoking statusPulm Pharmacol Ther211465117693107
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Chronic Conditions2004Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary careThorax59Suppl 11232
   Google Scholar
• NicholKLBakenLNelsonA1999Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung diseaseAnn Intern Med13039740310068413
   PubMed Web of Science ®Google Scholar
• NiewoehnerDERiceKCoteC2005Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trialAnn Intern Med1433172616144890
   PubMed Web of Science ®Google Scholar
• Nocturnal Oxygen Therapy Trial Group1980Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial GroupAnn Intern Med9339186776858
   PubMed Web of Science ®Google Scholar
• ObaY2007Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary diseaseMayo Clin Proc825758217493425
   PubMed Web of Science ®Google Scholar
• PauwelsRABuistASCalverleyPM2001Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summaryAm J Respir Crit Care Med16312567611316667
   PubMedGoogle Scholar
• PowrieDJWilkinsonTMDonaldsonGC2007Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPDEur Respir J30472817504798
   PubMed Web of Science ®Google Scholar
• QaseemASnowVShekelleP2007Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of PhysiciansAnn Intern Med147633817975186
   PubMed Web of Science ®Google Scholar
• RabeKFHurdSAnzuetoA2007Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med1765325517507545
   PubMed Web of Science ®Google Scholar
• RandCSNidesMCowlesMK1995Long-term metered-dose inhaler adherence in a clinical trial. The Lung Health Study Research GroupAm J Respir Crit Care Med15258087633711
   PubMed Web of Science ®Google Scholar
• RennardSIAndersonWZuWallackR2001Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med16310879211316640
   PubMed Web of Science ®Google Scholar
• SalpeterSROrmistonTMSalpeterEE2004Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysisChest12523092115189956
   PubMed Web of Science ®Google Scholar
• SestiniPRenzoniERobinsonS2002Short-acting beta 2 agonists for stable chronic obstructive pulmonary diseaseCochrane Database Syst RevCD00149512519559
   PubMedGoogle Scholar
• SinghSLokeYKFurbergCD2008Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysisJAMA30014395018812535
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennS2008A 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med35915435418836213
   PubMed Web of Science ®Google Scholar
• van NoordJASmeetsJJCustersFL2002Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary diseaseEur Respir J196394411998992
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensE2005Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEur Respir J262142216055868
   PubMed Web of Science ®Google Scholar
• VerkindreCBartFAguilaniuB2006The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary diseaseRespiration73420716484769
   PubMed Web of Science ®Google Scholar
• VinckenWvan NoordJAGreefhorstAP2002Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropiumEur Respir J192091611871363
   PubMed Web of Science ®Google Scholar
• VoshaarTLapidusRMaleki-YazdiR2008A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPDRespir Med1021324117996436
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTA2008The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med177192617916806
   PubMed Web of Science ®Google Scholar